Physician profile
Mary Bailey
NPI 1558543686
$629,500.66
in general payments reported to CMS, 2019-2025
18 companies · $98K in 2025
The $98K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148K · 2020: $50K · 2021: $52K · 2022: $109K · 2023: $113K · 2024: $59K · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $224K · Consulting Fee: $21K · Travel and Lodging: $13K · Honoraria: $7,400 · Food and Beverage: $5,140 · Education: $75.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $223,521.00 |
| Consulting Fee | $21,463.00 |
| Travel and Lodging | $13,364.91 |
| Honoraria | $7,400.00 |
| Food and Beverage | $5,140.46 |
| Education | $75.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $157,851.68 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Tg Therapeutics, INC. | $140,214.86 | 2021-2025 | |
| Emd Serono, INC. | $87,475.68 | 2019-2025 | Mavenclad, Mavenclad |
| Genentech USA, INC. | $79,431.00 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $51,796.22 | 2019-2023 | Kesimpta |
| Celgene Corporation | $39,155.74 | 2019-2024 | Zeposia |
| Genzyme Corporation | $34,733.31 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $17,055.18 | 2019-2025 | Ultomiris |
| Horizon Therapeutics Plc | $10,680.01 | 2022-2023 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $10,642.72 | 2020-2023 | Zeposia |
| Genentech, INC. | $218.29 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Amgen INC. | $83.07 | 2024-2025 | Uplizna, Evenity, Prolia |
| Teleflex LLC | $55.18 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $29.73 | 2023 | Nuedexta |
| Axonics, INC. | $26.83 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $24.95 | 2024 | |
| Acorda Therapeutics, INC | $13.96 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.